SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

Recent Analyst Ratings for
$HRMY

$HRMY
Leadership Updates

$HRMY
Large Ownership Changes

Chat with this insight

Live Leadership Updates

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN

This live feed shows all institutional transactions in real time.

2/13/24 7:06:51 PM ET

$HRMY

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $HRMY alert in real time by email

SC 13G/A 1 d778408dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Harmony Biosciences Holdings, Inc

(Name of Issuer)

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

413197 104

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 413197 104		13G		Page 2 of 12 Pages


CUSIP No. 413197 104		13G		Page 3 of 12 Pages


CUSIP No. 413197 104		13G		Page 4 of 12 Pages


CUSIP No. 413197 104		13G		Page 5 of 12 Pages


CUSIP No. 413197 104		13G		Page 6 of 12 Pages


CUSIP No. 413197 104		13G		Page 7 of 12 Pages


CUSIP No. 413197 104		13G		Page 8 of 12 Pages


CUSIP No. 413197 104		13G		Page 9 of 12 Pages

Item 1(a).

Name of Issuer:

Harmony Biosciences Holdings, Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

630 W. Germantown Pike, Suite 215, Plymouth Meeting, Pennsylvania, 19462

Item 2(a).

Name of Person Filing:

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

1) Valor IV Pharma Holdings, LLC

2) Valor Equity Partners IV L.P.

3) Valor Equity Partners IV-A L.P.

4) Valor Equity Partners IV-B L.P.

5) Valor Equity Associates IV L.P.

6) Valor Equity Capital IV LLC

7) Valor Management L.P.

8) Antonio J. Gracias

9) Juan A. Sabater

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address of each Reporting Person is 320 North Sangamon Street, Suite 1200, Chicago, IL 60607.

Item 2(c).

Citizenship:

Each entity Reporting Person is organized under the laws of Delaware. Messrs. Gracias and Sabater are citizens of the United States.

Item 2(d).

Title of Class of Securities:

Common Stock, $0.00001 par value per share

Item 2(e).

CUSIP Number:

413197104

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), indicate type of person filing.

Not applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned: See row 9 of the cover pages.

(b)

Percent of class: See row 11 of the cover pages.

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or direct the vote: See row 5 of the cover pages.


CUSIP No. 413197 104		13G		Page 10 of 12 Pages

(ii)

Shared power to vote or direct the vote: See row 6 of the cover page.

(iii)

Sole power to dispose or to direct the disposition of: See row 7 of the cover pages.

(iv)

Shared power to dispose or to direct the disposition of: See row 8 of the cover pages.

As of December 31, 2023, Valor IV Pharma Holdings, LLC was the holder of record of the shares reported herein. Valor Management L.P. is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P., or the “Valor Funds.” The Valor Funds are the sole members of Valor IV Pharma Holdings, LLC. By virtue of their positions with Valor Management L.P., each of Messrs. Gracias and Sabater may be deemed to share beneficial ownership over the shares held of record by Valor IV Pharma Holdings, LLC; however, each disclaims beneficial ownership of such shares for purposes of Sections 13(d) or 13(g) of the Act and the inclusion of such persons in this Schedule 13G shall not be construed as an admission that such persons are, for the purposes of Sections 13(d) or 13(g) of the Act, the beneficial owner of any securities covered by this Schedule 13G.

Percent of class is based on (i) the number of shares that may be deemed to be beneficially owned by each Reporting Person as of December 31, 2023 and (ii) the number of shares of common stock outstanding as of October 27, 2023 (58,571,944 shares) as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission on October 31, 2023.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


February 13, 2024	Valor IV Pharma Holdings, LLC

	By: Valor Equity Associates IV L.P., as general partner of its members

	By:	Valor Equity Capital IV LLC, its general partner

	By:	Valor Management L.P., its managing member

	By:	/s/ Antonio J. Gracias
		Name: Antonio J. Gracias
		Title: CEO

	Valor Equity Partners IV L.P.

	By:	Valor Equity Associates IV L.P., its general partner

	By:	Valor Equity Capital IV LLC, its general partner

	By:	Valor Management L.P., its managing member

	By:	/s/ Antonio J. Gracias
		Name: Antonio J. Gracias
		Title: CEO

	Valor Equity Partners IV-A L.P.

	By:	Valor Equity Associates IV L.P., its general partner

	By:	Valor Equity Capital IV LLC, its general partner

	By:	Valor Management L.P., its managing member

	By:	/s/ Antonio J. Gracias
		Name: Antonio J. Gracias
		Title: CEO

	Valor Equity Partners IV-B L.P.

	By:	Valor Equity Associates IV L.P., its general partner

	By:	Valor Equity Capital IV LLC, its general partner

	By:	Valor Management L.P., its managing member

	By:	/s/ Antonio J. Gracias
		Name : Antonio J. Gracias
		Title: CEO


				Valor Equity Associates IV L.P.

				By:		Valor Equity Capital IV LLC, its general partner

				By:		Valor Management L.P., its managing member

				By:		/s/ Antonio J. Gracias
						Name: Antonio J. Gracias
						Title: CEO

				Valor Equity Capital IV LLC

				By:		Valor Management L.P., its managing member

				By:		/s/ Antonio J. Gracias
						Name: Antonio J. Gracias
						Title: CEO

				Valor Management L.P.

				By:		/s/ Antonio J. Gracias
						Name: Antonio J. Gracias
						Title: CEO

				/s/ Antonio J. Gracias
				Name: Antonio J. Gracias

				/s/ Juan A. Sabater
				Name: Juan A. Sabater

Get the next $HRMY alert in real time by email

Date	Price Target	Rating	Analyst
6/2/2025	$61.00	Outperform	Oppenheimer
2/11/2025	$55.00	Buy	Deutsche Bank
12/17/2024	$75.00	Buy	H.C. Wainwright
10/10/2024		Outperform	Raymond James
9/10/2024	$56.00	Buy	UBS
6/21/2024	$48.00	Buy	Citigroup
1/2/2024	$30.00	Neutral → Underperform	BofA Securities
9/25/2023	$40.00 → $31.00	Neutral → Sell	Goldman

NAME OF REPORTING PERSON

Valor IV Pharma Holdings, LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware